1. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. (2010) Recent advances in cancer therapy: an overview. Current Pharmaceutical Design. 16(1): 3-10.
2. Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C, Sezer O. Bone markers in multiple myeloma. European Journal of Cancer. 2006; 42(11): 1544-53.
3. Silvestris F, Lombardi L, De Matteo M, Bruno A, Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leukocyte Research. 2007; 31(2): 129-38.
4. Armirage JO, Longo DL. Harrison's principles of internal medicine. 16th ed. USA. McGraw-Hill componies,Inc. 2005: 641-655.
5. Bierman J, Harris N, Armitage JO. Cecil textbook of medicine. 22nd ed. California. Elsevir Inc. 2004: 1174-1183.
6. Nooka A, Lonial S. Sequential or combination therapy for multiple myeloma. Expert Reviews in Hematology. 2012; 5(5): 533-45.
7. Slavin S, Morecki S, Weiss L, Or R. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Critcal Reviews in Oncology/Hematology. 2003; 46(2): 139-63.
8. Ruan WJ, Lai MD, Zhou JG. Anticancer effects of chines herbal medicine, science or myth. Journal of Zhejiang University Science. 2006; 7(12): 1006-14.
9. Ranga RS. A herbal medicine for treatment of lung cancer. Molecular Cell 2005; 280 (1-2): 125-33.
10. Yaraee R, Ghazanfari T, Shams JAD, Esmaeili M. Jamali D. The Eeffect of herbal extract SIM5 on lymphoma cell lines and blood mononuclear cells. Daneshvar Medicine 2008; 15(73): 73-78.
11. Yaraee R, Kamalinejad M, Ghazanfari T, Eghtedardoost M. Discriminative Effect of SIM5 and its fractions on normal and cancerous lymphocytes. The 17th national & 5th International Conference of Biology of Iran. 2012.
12. Burton JD. The MTT assay to evaluate chemosensitivity. Methods in Molecular Medicine. 2005; 110: 69-78.
13. Morgan DML. Tetrazolium (MTT) Assay for Cellular Viability and Activity. Methods in Molecular Medicine. 1998; 79: 179-83.
14. Yaraee R. , Kamalinejad M., Rajabian T. Eghtedardoost, M , Jamali D. Comparison of toxic effects of SIM5 and its fractions on normal resting, activated and cancerous cells. daneshvarmed. 2016; 24(125):1-12.
15. Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GT, Roccaro AM, Anderson KC, Ghobrial IM. Targeting the bone marrow microenvironment in multiple myeloma. Immunological Reviews. 2015 Jan; 263(1): 160-72.
16. Rebersek K, Cernelc P, Podgornik H. Evaluation of multiple myeloma cell apoptosis in primary bone marrow samples. Clinical laboratory. 2013; 59(3-4): 389-95.
)